ClinicalTrials.gg
CompletedNCT06293742Updated Jul 22, 2024

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

A Phase 1 interventional study of ECC5004 and Midazolam in Type 2 Diabetes Mellitus, sponsored by Eccogene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
11th of 18
48 · median 57
Started
2024
with 4 others
Phase 1
11 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
4 of 18
Eccogene

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 1, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.

Read the detailed description

The study consists of four parts (Part A, Part B, optional Part C and optional Part D), each with approximately 16 healthy participants enrolled. Part A and optional Part C of the study will have the same study design with two treatment periods, except that ECC5004 will be administered at a higher dose level in the optional Part C. Part B and optional Part D of the study will have the same study design with five treatment periods, except that ECC5004 will be administered at a higher dose level in optional Part D. Rosuvastatin and Digoxin will be administered alone or in combination with EC5004 in Part A and optional Part C. Atorvastatin and Midazolam will be administered alone or in combination with ECC5004 in Part B and optional Part D. The conduct of Part C and Part D with an increased dose of ECC5004 may be conducted as optional parts.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants of non- (NCBP) between the ages of 18 to 65 years of age
  • of 18.0 to 32.0 kg/m2
  • Female participants who are , confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence
  • Male participants agree to use , or agree to practice true abstinence
  • No findings in physical examination, 12-lead (ECG), vital sign measurements, clinical laboratory evaluations, concomitant medications, or medical/psychiatric history
  • Able to understand and sign and date

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, planning to become pregnant, or breastfeeding during the study or within 3 months after the study
  • Concomitant participation in any study of any nature
  • Blood loss of non-physiological reasons ≥ 200 ml (i.e., trauma, blood collection, blood donation) within 2 months prior to the first dose of study treatment, or plan to donate blood during this trial and within 1 month after the last dose of study treatment
  • Serum calcitonin > 20 ng/L
  • acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems
  • Individual or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or suspected MTC
  • History of pancreatitis
  • Significant allergic reaction to active ingredients or of the study drug
  • Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study
  • Used or plan to use any drugs or substances that can modulate the activity of within at least 14 days prior to the first dose of study treatment until after their final follow up visit
  • Use of drugs with enzyme-inducing properties such as St. John's Wort within 3 weeks prior to the first dose of study treatment until after their final follow up visit
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Digoxin, Rosuvastatin, ECC5004 (Part A)

    Part A consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.

    Drug: ECC5004 · Drug: Rosuvastatin · Drug: Digoxin

  • Experimental
    Midazolam, Atorvastatin, ECC5004 (Part B)

    Part B consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.

    Drug: ECC5004 · Drug: Midazolam · Drug: Atorvastatin

  • Experimental
    Digoxin, Rosuvastatin, ECC5004 (optional Part C)

    Optional Part C consists of 2 treatment periods. Participants will receive Digoxin and Rosuvastatin administered alone in treatment period 1 and in combination with ECC5004 in treatment period 2.

    Drug: ECC5004 · Drug: Rosuvastatin · Drug: Digoxin

  • Experimental
    Midazolam, Atorvastatin, ECC5004 (optional Part D)

    Optional Part D consists of 5 treatment periods. In treatment period 1, participants will receive Midazolam administered alone followed by treatment period 2 in which participants will receive Atorvastatin administered alone. In treatment period 3, participants will receive ECC5004 alone. In treatment period 4, participants will receive ECC5004 in combination with Midazolam. In treatment period 5, ECC5004 will be administered alone and co-administered with Atorvastatin.

    Drug: ECC5004 · Drug: Midazolam · Drug: Atorvastatin

Interventions

  • ECC5004 tablet will be administered orally.

  • Midazolam will be administered orally.

  • Rosuvastatin will be administered orally.

  • Digoxin will be administered orally.

  • Atorvastatin will be administered orally.

06

What researchers measure

Primary outcomes

  1. Atorvastatin PK parameters: AUC(0-tlast)

    Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration

    Time frame: Part B and optional Part D: up to Day 34

  2. Atorvastatin PK parameters: AUC(0-inf)

    Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity

    Time frame: Part B and optional Part D: up to Day 34

  3. Atorvastatin PK parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Part B and optional Part D: up to Day 34

  4. Rosuvastatin PK parameters: AUC(0-tlast)

    Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration

    Time frame: Part A and optional Part C: up to Day 11

  5. Rosuvastatin PK parameters: AUC(0-inf)

    Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity

    Time frame: Part A and optional Part C: up to Day 11

  6. Rosuvastatin PK parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Part A and optional Part C: up to Day 11

  7. Digoxin PK parameters: AUC(0-tlast)

    Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration

    Time frame: Part A and optional Part C: up to Day 11

  8. Digoxin PK parameters: AUC(0-inf)

    Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity

    Time frame: Part A and optional Part C: up to Day 11

  9. Digoxin PK parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Part A and optional Part C: up to Day 11

  10. Midazolam PK parameters: AUC(0-tlast)

    Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non Zero Concentration

    Time frame: Part B and optional Part D: up to Day 34

  11. Midazolam PK parameters: AUC(0-inf)

    Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity

    Time frame: Part B and optional Part D: up to Day 34

  12. Midazolam PK parameters: Cmax

    Maximum observed plasma concentration

    Time frame: Part B and optional Part D: up to Day 34

Secondary outcomes

  1. ECC5004 Safety parameters: Number of participants with adverse events (AEs)

    Safety Assessment evaluated through adverse events

    Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40

  2. ECC5004 Safety parameters: Number of participants with vital sign abnormalities

    Safety Assessment evaluated through vital signs

    Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40

  3. ECC5004 Safety parameters: Number of participants with electrocardiogram (ECG) abnormalities

    Safety Assessment evaluated through electrocardiograms (ECGs)

    Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40

  4. ECC5004 Safety parameters: Number of participants with physical examination abnormalities

    Safety Assessment evaluated through physical examination

    Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40

  5. ECC5004 Safety parameters: Number of participants with clinical laboratory abnormalities

    Safety Assessment evaluated through clinical laboratory assessments

    Time frame: Part A and optional Part C: up to Day 16; Part B and optional Part D: up to Day 40

  6. Atorvastatin safety parameters: Number of participants with adverse events (AEs)

    Safety Assessment evaluated through adverse events

    Time frame: Part B and optional Part D: up to Day 40

  7. Atorvastatin safety parameters: Number of participants with vital sign abnormalities

    Safety Assessment evaluated through vital signs

    Time frame: Part B and optional Part D: up to Day 40

  8. Atorvastatin safety parameters: Number of participants with electrocardiogram (ECG)

    Safety Assessment evaluated through electrocardiograms (ECGs)

    Time frame: Part B and optional Part D: up to Day 40

  9. Atorvastatin safety parameters: Number of participants with physical examination abnormalities

    Safety Assessment evaluated through physical examination

    Time frame: Part B and optional Part D: up to Day 40

  10. Atorvastatin safety parameters: Number of participants with clinical laboratory abnormalities

    Safety Assessment evaluated through clinical laboratory assessments

    Time frame: Part B and optional Part D: up to Day 40

  11. Rosuvastatin safety parameters: Number of participants with adverse events (AEs)

    Safety Assessment evaluated through adverse events

    Time frame: Part A and optional Part C: up to Day 16

  12. Rosuvastatin safety parameters: Number of participants with vital sign abnormalities

    Safety Assessment evaluated through vital signs

    Time frame: Part A and optional Part C: up to Day 16

  13. Rosuvastatin safety parameters: Number of participants with electrocardiogram (ECG) abnormalities

    Safety Assessment evaluated through electrocardiograms (ECGs)

    Time frame: Part A and optional Part C: up to Day 16

  14. Rosuvastatin safety parameters: Number of participants with physical examination abnormalities

    Safety Assessment evaluated through physical examination

    Time frame: Part A and optional Part C: up to Day 16

  15. Rosuvastatin safety parameters: Number of participants with clinical laboratory abnormalities

    Safety Assessment evaluated through clinical laboratory assessments

    Time frame: Part A and optional Part C: up to Day 16

  16. Digoxin safety parameters: Number of participants with adverse events (AEs)

    Safety Assessment evaluated through adverse events

    Time frame: Part A and optional Part C: up to Day 16

  17. Digoxin safety parameters: Number of participants with vital sign abnormalities

    Safety Assessment evaluated through vital signs

    Time frame: Part A and optional Part C: up to Day 16

  18. Digoxin safety parameters: Number of participants with electrocardiogram (ECG) abnormalities

    Safety Assessment evaluated through electrocardiograms (ECGs)

    Time frame: Part A and optional Part C: up to Day 16

  19. Digoxin safety parameters: Number of participants with physical examination abnormalities

    Safety Assessment evaluated through physical examination

    Time frame: Part A and optional Part C: up to Day 16

  20. Digoxin safety parameters: Number of participants with clinical laboratory abnormalities

    Safety Assessment evaluated through clinical laboratory assessments

    Time frame: Part A and optional Part C: up to Day 16

  21. Midazolam safety parameters: Number of participants with adverse events (AEs)

    Safety Assessment evaluated through adverse events

    Time frame: Part B and optional Part D: up to Day 40

  22. Midazolam safety parameters: Number of participants with vital sign abnormalities

    Safety Assessment evaluated through vital signs

    Time frame: Part B and optional Part D: up to Day 40

  23. Midazolam safety parameters: Number of participants with electrocardiogram (ECG) abnormalities

    Safety Assessment evaluated through electrocardiograms (ECGs)

    Time frame: Part B and optional Part D: up to Day 40

  24. Midazolam safety parameters: Number of participants with physical examination abnormalities

    Safety Assessment evaluated through physical examination

    Time frame: Part B and optional Part D: up to Day 40

  25. Midazolam safety parameters: Number of participants with clinical laboratory abnormalities

    Safety Assessment evaluated through clinical laboratory assessments

    Time frame: Part B and optional Part D: up to Day 40

  26. ECC5004 PK parameters: AUC (0-τ)

    Area under the Plasma Concentration-Time Curve during the Dosing Interval

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

  27. ECC5004 PK parameters: AUC(0-24)

    Area under the Plasma Concentration-Time Curve from Time 0 to 24 Hours Post-dose

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

  28. ECC5004 PK parameters: tmax

    Time of the maximum observed plasma concentration

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

  29. ECC5004 PK parameters: t1/2

    Apparent terminal elimination half-life

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

  30. ECC5004 PK parameters: CL/F

    Apparent Clearance

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

  31. ECC5004 PK parameters: Ctau

    Observed Concentration at the End of the Dosing Interval

    Time frame: Part A and optional Part C: up to Day 11; Part B and optional Part D: up to Day 34

07

Study locations

1 site
  • Eccogene Investigational Site
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2024, 2 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 5, 2024
StartActual
Feb 8, 2024
Primary completionActual
Apr 15, 2024
CompletionActual
Apr 15, 2024
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06293742
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Feb 8, 2024
Primary completion
Apr 15, 2024
Completion
Apr 15, 2024
Last update
Jul 22, 2024

Study contacts

Eccogene
study director · Eccogene Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elecoglipron · Atorvastatin

Start the discussion